Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

Annals of Oncology

Volumn 13, Issue 9, 2002, Pages 1356-1363

  Verhoef, G ^a   Spaepen, K ^a   Stroobants, S ^a   Dupont, P ^a   Vandenberghe, P ^a   Thomas, J ^a   De Groot, T ^a   Balzarini, J ^a   De Wolf Peeters, C ^a   Mortelmans, L ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

18F FDG PET; Non Hodgkin's lymphoma; Therapy monitoring

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DIURETIC AGENT; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISOLONE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVALUATION STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, HIGH-GRADE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREDNISOLONE; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036739436     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf256     Document Type: Article

References (27)

1. Lyphoma 2000. The first international symposium on biology and treatment of aggressive lymphomas. The stagnation seems to be over. Ann Hematol 2001; 80 (Suppl 3): B1-B2.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
3. Armitage J, Weisenburger D, Hutchins M et al. Chemotherapy for diffuse large-cell lymphoma: rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4: 160-164.
4. Engelhard MPM, Meusers P, Brittinger G. et al. Prospective multi-center trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/ IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol 1991; 2: 177-180.
5. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931-933.
6. Thomas F, Cosset JM, Cherel P et al. Thoracic CT: scanning follow-up of residual mediastinal masses after treatment of Hodgkin's disease. Radiother Oncol 1988; 11: 119-122.
7. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for the detection of lymphoma. J Nucl Med 1987; 28: 288-292.
8. 18F]FDG-PET a valid alternative to convention diagnostic methods? J Clin Oncol 2001; 19: 414-419.
9. Kluin-Nelemans H, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001; 93: 22-30.
10. Atra A, Imeson JD, Hobson R et al. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 2000; 82: 1396-1402.
11. Shepp LA, Vardi Y. Maximum likelihood reconstruction for emission tomography. IEEE Trans Med Imaging 1982; 1: 113-122.
12. Cheson BD, Horning S-J, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244.
13. Kaplan ES, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 58: 457-481.
14. Mantel H, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst 1959; 22: 719-748.
15. Cox R. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
16. Harris NL, Jaffe E-S, Stein H et al. A revised European-American classification of lymphoid neoplasm's: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
17. Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy in lymphoma patients. Semin Nucl Med 1995; 25: 60-71.
18. Vose JM, Bierman PJ, Anderson JR et al. Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 2473-2479.
19. Kaplan W, Jochelson MS, Herman TS et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8: 1966-1970.
20. 67Ga scintigraphy. Radiology 2000; 214: 253-257.
21. De Wit M, Bumann D, Beyer W et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8 (Suppl 1): S57-S60.
22. Zinzani PL, Magagnoli M, Chierichetti F et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10: 1181-1184.
23. Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using fluorine-18-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has a higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433.
24. Dimitrakopoulou-Strauss A, Struass LG, Goldschmidt H et al. Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22: 434-442.
25. Hoekstra OS, Van lingen A, Ossenkoppele GJ et al. Early response monitoring in malignant lymphoma using fluorine-18-fluorodeoxy-glucose single-photon emission tomography. Eur J Nucl Med 1993; 20: 1214-1220.
26. Römer W, Hanauske AR, Ziegler S et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
27. Jerusalem G, Beguin Y, Fassotte M-F et al. Persistent tumor fluorine-18-fluorodeoxyglucose uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85: 613-618.